RecruitingEarly Phase 1NCT06451172
Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis
Sponsor
Eye & ENT Hospital of Fudan University
Enrollment
20 participants
Start Date
Oct 11, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to evaluate the safety and efficacy of GP-asPNA for in vivo treatment of severe antibiotic resistant bacterial keratitis.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called ASO for people with antibacterial therapy, antibiotic-resistant bacteria, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGASO
Anticipated 20 Participants will receive a single group administered via eye drops in the study eye.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06451172
Related Trials
Screening for Research Participants
NCT006550961 location
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
NCT0689144317 locations
Stem Cell Ophthalmology Treatment Study II
NCT030115414 locations
OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity
NCT0714078323 locations
Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene
NCT0662717928 locations